DDInter1837 DDInter1008
Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue to be used in topical formulations.
Toremifene {u} may lead to a major life threatening interaction when taken with {v} Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Toremifene {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ketoconazole
Toremifene {u} (Compound) upregulates {v} (Gene) FDFT1
FDFT1 {u} (Gene) is upregulated by {v} (Compound) Ketoconazole
Toremifene {u} (Compound) causes {v} (Side Effect) Menopausal symptoms
Menopausal symptoms {u} (Side Effect) is caused by {v} (Compound) Ketoconazole
Toremifene {u} (Compound) upregulates {v} (Gene) CYP51A1
CYP51A1 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Ketoconazole
Toremifene {u} may lead to a major life threatening interaction when taken with {v} Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Itraconazole
Itraconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Toremifene {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Itraconazole
Itraconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Toremifene {u} (Compound) upregulates {v} (Gene) FDFT1
FDFT1 {u} (Gene) regulates {v} (Gene) SLC2A6
SLC2A6 {u} (Gene) is upregulated by {v} (Compound) Ketoconazole
Toremifene {u} (Compound) upregulates {v} (Gene) SLC2A6
SLC2A6 {u} (Gene) is regulated by {v} (Gene) FDFT1
FDFT1 {u} (Gene) is upregulated by {v} (Compound) Ketoconazole
Toremifene {u} (Compound) upregulates {v} (Gene) INSIG1
INSIG1 {u} (Gene) is upregulated by {v} (Compound) Itraconazole
Itraconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Toremifene may lead to a major life threatening interaction when taken with Posaconazole and Posaconazole (Compound) resembles Ketoconazole (Compound)
Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ketoconazole (Compound)
Toremifene (Compound) upregulates FDFT1 (Gene) and FDFT1 (Gene) is upregulated by Ketoconazole (Compound)
Toremifene (Compound) causes Menopausal symptoms (Side Effect) and Menopausal symptoms (Side Effect) is caused by Ketoconazole (Compound)
Toremifene (Compound) upregulates CYP51A1 (Gene) and CYP51A1 (Gene) is bound by Ketoconazole (Compound) and CYP51A1 (Gene) is upregulated by Ketoconazole (Compound)
Toremifene may lead to a major life threatening interaction when taken with Posaconazole and Posaconazole (Compound) resembles Itraconazole (Compound) and Itraconazole (Compound) resembles Ketoconazole (Compound)
Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Itraconazole (Compound) and Itraconazole (Compound) resembles Ketoconazole (Compound)
Toremifene (Compound) upregulates FDFT1 (Gene) and FDFT1 (Gene) regulates SLC2A6 (Gene) and SLC2A6 (Gene) is upregulated by Ketoconazole (Compound)
Toremifene (Compound) upregulates SLC2A6 (Gene) and SLC2A6 (Gene) is regulated by FDFT1 (Gene) and FDFT1 (Gene) is upregulated by Ketoconazole (Compound)
Toremifene (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is upregulated by Itraconazole (Compound) and Itraconazole (Compound) resembles Ketoconazole (Compound)